U.S. government expands assistance to J&J COVID-19 vaccine research

By The Science Advisory Board staff writers

The Biomedical Advanced Research and Development Authority (BARDA) is expanding its partnership with Johnson & Johnson by providing additional support for the ongoing development of its investigational COVID-19 vaccine candidate.

Under the amendment to the initial agreement, Janssen will commit approximately $604 million and BARDA will commit approximately $454 million to support the ongoing phase III Ensemble clinical trial evaluating the investigational COVID-19 vaccine candidate as a single-dose in up to 60,000 volunteers worldwide.

Copyright © 2020 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking